利拉鲁肽对肥胖多囊卵巢综合征患者卵巢颗粒细胞瘦素启动子甲基化的影响

IF 1.7 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Tohoku Journal of Experimental Medicine Pub Date : 2025-07-01 Epub Date: 2025-01-30 DOI:10.1620/tjem.2025.J009
Lina Su, Xiaoxia Hao, Wenhong Lu
{"title":"利拉鲁肽对肥胖多囊卵巢综合征患者卵巢颗粒细胞瘦素启动子甲基化的影响","authors":"Lina Su, Xiaoxia Hao, Wenhong Lu","doi":"10.1620/tjem.2025.J009","DOIUrl":null,"url":null,"abstract":"<p><p>Serum leptin (LEP) is elevated in polycystic ovary syndrome (PCOS) patients, especially in obese PCOS patients, which may link to the etiology and development of PCOS. Obesity adversely affects female fertility, and most PCOS patients are obese. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, regulates adipokine production, causes weight loss, and regulates ovarian physiology to improve or manage reproductive status, thus ameliorating obesity and PCOS. This study investigated the impact of liraglutide on LEP promoter methylation levels in ovarian granulosa cells of obese PCOS patients to seek possible potential targets for the clinical treatment. This prospective observational study enrolled 348 PCOS patients with strong fertility desire in our hospital during March 2020-January 2022 who were planned to undergo in vitro fertilization and embryo transfer. Based on the inclusion and exclusion criteria, 207 eligible patients (72 non-obese and 135 obese PCOS patients, 23-37 year-old) were enrolled. Obese PCOS patients [body mass index (BMI) ≥ 25 kg/m<sup>2</sup>] received liraglutide treatment. Obese PCOS patients exhibited elevated BMI, fasting insulin, fasting blood glucose, HOMA-IR, triglyceride, estradiol, and testosterone levels and reduced high-density lipoprotein cholesterol, luteinizing hormone (LH), LH/follicle-stimulating hormone ratio, and LEP promoter methylation. Liraglutide increases LEP promoter methylation, decreases LEP levels, and affects sex hormone secretion, providing a reference for the investigation of the mechanism of liraglutide in obese PCOS patients. Additionally, weight and fat loss, decreased serum and follicular fluid LEP levels, and increased LEP promoter methylation levels in ovarian granulosa cells may be crucial strategies for treating obese PCOS patients.</p>","PeriodicalId":23187,"journal":{"name":"Tohoku Journal of Experimental Medicine","volume":" ","pages":"199-207"},"PeriodicalIF":1.7000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of Liraglutide on Leptin Promoter Methylation in Ovarian Granulosa Cells of Obese Polycystic Ovary Syndrome Patients.\",\"authors\":\"Lina Su, Xiaoxia Hao, Wenhong Lu\",\"doi\":\"10.1620/tjem.2025.J009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Serum leptin (LEP) is elevated in polycystic ovary syndrome (PCOS) patients, especially in obese PCOS patients, which may link to the etiology and development of PCOS. Obesity adversely affects female fertility, and most PCOS patients are obese. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, regulates adipokine production, causes weight loss, and regulates ovarian physiology to improve or manage reproductive status, thus ameliorating obesity and PCOS. This study investigated the impact of liraglutide on LEP promoter methylation levels in ovarian granulosa cells of obese PCOS patients to seek possible potential targets for the clinical treatment. This prospective observational study enrolled 348 PCOS patients with strong fertility desire in our hospital during March 2020-January 2022 who were planned to undergo in vitro fertilization and embryo transfer. Based on the inclusion and exclusion criteria, 207 eligible patients (72 non-obese and 135 obese PCOS patients, 23-37 year-old) were enrolled. Obese PCOS patients [body mass index (BMI) ≥ 25 kg/m<sup>2</sup>] received liraglutide treatment. Obese PCOS patients exhibited elevated BMI, fasting insulin, fasting blood glucose, HOMA-IR, triglyceride, estradiol, and testosterone levels and reduced high-density lipoprotein cholesterol, luteinizing hormone (LH), LH/follicle-stimulating hormone ratio, and LEP promoter methylation. Liraglutide increases LEP promoter methylation, decreases LEP levels, and affects sex hormone secretion, providing a reference for the investigation of the mechanism of liraglutide in obese PCOS patients. Additionally, weight and fat loss, decreased serum and follicular fluid LEP levels, and increased LEP promoter methylation levels in ovarian granulosa cells may be crucial strategies for treating obese PCOS patients.</p>\",\"PeriodicalId\":23187,\"journal\":{\"name\":\"Tohoku Journal of Experimental Medicine\",\"volume\":\" \",\"pages\":\"199-207\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tohoku Journal of Experimental Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1620/tjem.2025.J009\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tohoku Journal of Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1620/tjem.2025.J009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

多囊卵巢综合征(PCOS)患者,尤其是肥胖多囊卵巢综合征(PCOS)患者血清瘦素(LEP)升高,可能与多囊卵巢综合征的病因和发展有关。肥胖对女性生育能力有不利影响,多数多囊卵巢综合征患者肥胖。利拉鲁肽是一种胰高血糖素样肽-1 (GLP-1)类似物,可调节脂肪因子的产生,导致体重减轻,并调节卵巢生理以改善或管理生殖状态,从而改善肥胖和多囊卵巢综合征。本研究探讨利拉鲁肽对肥胖PCOS患者卵巢颗粒细胞LEP启动子甲基化水平的影响,寻求临床治疗可能的潜在靶点。本前瞻性观察研究于2020年3月- 2022年1月在我院纳入348例生育意愿强烈的PCOS患者,计划进行体外受精和胚胎移植。根据纳入和排除标准,纳入207例符合条件的PCOS患者(非肥胖患者72例,肥胖患者135例,年龄23-37岁)。肥胖PCOS患者[体重指数(BMI)≥25 kg/m2]接受利拉鲁肽治疗。肥胖多囊卵巢综合征患者表现为BMI、空腹胰岛素、空腹血糖、HOMA-IR、甘油三酯、雌二醇和睾酮水平升高,高密度脂蛋白胆固醇、黄体生成素(LH)、LH/促卵泡激素比值和LEP启动子甲基化降低。利拉鲁肽增加LEP启动子甲基化,降低LEP水平,影响性激素分泌,为探讨利拉鲁肽治疗肥胖型PCOS患者的作用机制提供参考。此外,减轻体重和脂肪,降低血清和卵泡液LEP水平,增加卵巢颗粒细胞中LEP启动子甲基化水平可能是治疗肥胖PCOS患者的关键策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effects of Liraglutide on Leptin Promoter Methylation in Ovarian Granulosa Cells of Obese Polycystic Ovary Syndrome Patients.

Serum leptin (LEP) is elevated in polycystic ovary syndrome (PCOS) patients, especially in obese PCOS patients, which may link to the etiology and development of PCOS. Obesity adversely affects female fertility, and most PCOS patients are obese. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, regulates adipokine production, causes weight loss, and regulates ovarian physiology to improve or manage reproductive status, thus ameliorating obesity and PCOS. This study investigated the impact of liraglutide on LEP promoter methylation levels in ovarian granulosa cells of obese PCOS patients to seek possible potential targets for the clinical treatment. This prospective observational study enrolled 348 PCOS patients with strong fertility desire in our hospital during March 2020-January 2022 who were planned to undergo in vitro fertilization and embryo transfer. Based on the inclusion and exclusion criteria, 207 eligible patients (72 non-obese and 135 obese PCOS patients, 23-37 year-old) were enrolled. Obese PCOS patients [body mass index (BMI) ≥ 25 kg/m2] received liraglutide treatment. Obese PCOS patients exhibited elevated BMI, fasting insulin, fasting blood glucose, HOMA-IR, triglyceride, estradiol, and testosterone levels and reduced high-density lipoprotein cholesterol, luteinizing hormone (LH), LH/follicle-stimulating hormone ratio, and LEP promoter methylation. Liraglutide increases LEP promoter methylation, decreases LEP levels, and affects sex hormone secretion, providing a reference for the investigation of the mechanism of liraglutide in obese PCOS patients. Additionally, weight and fat loss, decreased serum and follicular fluid LEP levels, and increased LEP promoter methylation levels in ovarian granulosa cells may be crucial strategies for treating obese PCOS patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.60
自引率
4.50%
发文量
171
审稿时长
1 months
期刊介绍: Our mission is to publish peer-reviewed papers in all branches of medical sciences including basic medicine, social medicine, clinical medicine, nursing sciences and disaster-prevention science, and to present new information of exceptional novelty, importance and interest to a broad readership of the TJEM. The TJEM is open to original articles in all branches of medical sciences from authors throughout the world. The TJEM also covers the fields of disaster-prevention science, including earthquake archeology. Case reports, which advance significantly our knowledge on medical sciences or practice, are also accepted. Review articles, Letters to the Editor, Commentary, and News and Views will also be considered. In particular, the TJEM welcomes full papers requiring prompt publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信